Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Arena Pharmaceuticals ( ARNA) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, Arena Pharmaceuticals rose 91 cents (9.9%) to $10.11 on heavy volume. Throughout the day, 30.5 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 8.1 million shares. The stock ranged in a price between $9.31-$10.14 after having opened the day at $9.32 as compared to the previous trading day's close of $9.20. Other companies within the Health Care sector that increased today were: Cell Therapeutics ( CTIC), up 25.4%, Pacific Biosciences of California ( PACB), up 17.8%, Theratechnologies ( THER), up 15.8%, and Threshold Pharmaceuticals ( THLD), up 14.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.96 billion and is part of the drugs industry. Shares are down 0.2% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and five rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth.

On the negative front, Medical Action Industries ( MDCI), down 14.6%, CombiMatrix Corporation ( CBMX), down 10.6%, Aoxing Pharmaceutical Company ( AXN), down 10%, and Venaxis ( APPY), down 9.6%, were all laggards within the health care sector with Edwards Life ( EW) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says